Idec Pharmaceuticals has formed an $11.5-million research...
- Share via
Idec Pharmaceuticals has formed an $11.5-million research and development partnership with several organizations sponsored by Merrill Lynch and Morgan Stanley, two New York-based investment firms, the company said Thursday.
The partnership plans to complete development of a proprietary technology that Idec hopes will one day treat cancer of the immune system. The agreement announced Thursday covers Idec’s research into B-cell lymphomas and leukemias, cancers that affect more than 450,000 people in the United States, Europe and Japan.
Idec is conducting clinical trials to treat B-cell lymphomas at Stanford University, the Fred Hutchinson Cancer Research Center in Seattle, and at the UC San Diego Cancer Center.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
